

Clinical Pharmacy

Date _____
Page _____

Q1) Definition, scope, development of clinical pharmacy in India.

→ Definition :- The service provided by pharmacist to promote rational drug therapy that is safe, appropriate & cost effective are defined as clinical pharmacy.

OR

It is defined as the branch of pharmaceutical science dealing with utilization of pharmacist knowledge, skill and judgement related to biomedical and pharmaceutical science, to prove the safety, the cost and the precision of drug usage in patient care.

• Scope •

1) Preparation of patient medication History :-
- This will help in saving physician time and efforts.
- The result is faster & more accurate selection of drug therapy.

2) Rational prescription :- The clinical pharmacist can suggest the physician and help him to selecting right drug.

3) Bioequivalence

3) Bioequivalence & generic :- Selection of equivalence of formulations proper drug therapy based on bioequivalence & its dosage form.

4) Patient monitoring :- Help in identify the route of administration, signs symptoms overdose, side effect, contraindications etc.

5) Adverse drug reaction :- May suggest the alternate therapy by identify adverse drug.

6) Drug-drug interaction :- Inform the drug-drug or drug-food interaction to the physician.

7) Retail pharmacy store :- At retail store, clinical pharmacist maintain records, patient drug profile, prescription etc.

8) Discharge counselling & Drug therapy patient compliance can be improved several times by educating the patient at time of discharge.

9) Education program :- Conduct clinical trials & educate patients for the drug action & its importance.

10] Medical Audit :- The clinical pharmacist is either the initiator or a very member of a function committee.

Development

In 1953 - The term clinical pharmacy was first used.



In 1960 - The concept of clinical pharmacology started in 1960's with two incidence



In 1962 - The thalidomide tragedy, where it was found that consumption of popular sedative thalidomide result in birth of babies with deformed limbs



In 1968 :- Phenyltoin toxicity was reported in Australia which was because of change in formulation i.e. switching over from calcium sulfate to lactose as an inert excipient in tablet

Q2 Discuss about verbal & non verbal communication during counseling

→ Verbal communication :-

- It include ability to listen, understand and respond to what people say
- Also ability to interpret the non-verbal communication & respond in way that encourages continued interaction

(a) Active listening :- Good listening skill is important to promote a good interactive communication and obtained information

- focus on patient, family member or healthcare professional
- It make person feel like centre of attention
- Should have open, relaxed & unhurried attitude
- Give attention like keep eye contact, asking question etc.
- Tone & modulation of voice, in. b/w pauses make patient reliable.

(b) Observation & Assessment :-

- Effective two way communication requires continual observation, assessment of how the person is communicating.

Body language and gesture provide important clues for pharmacist, patient and health care professional.

(c) Open communication: Sitting or standing at eye level or lower. project a non-threatening, equalising body posture.

- Physically be close to patient, family member or healthcare professional.

(d) Language: - For reliable communication, use a language in which both parties are fluent & comfortable.

- Abbreviations & terms used for prescribing medicines represent a specialised type of communication.

- Try to avoid medical terms.

- Non-Verbal Communication

(I) Eye contact: - It includes confidence, attention and honesty to patient.

(II) Face expression: - An important indicator of emotional state.

- Do not do any facial expression related to diseases.

(III) Body Posture :- Message can be conveyed through body posture.

e.g. closed body posture :- Person sitting with his legs and arms crossed in front of body.

- A relaxed stance with uncrossed legs & arms lead to ~~to~~ open body posture.

(IV) Tone of voice :- Softer voice etc can also influence the communication.

(V) Proximity / closeness of position :- The pharmacist and patient must maintain a minimum distance of 45cm.

(VI) Another form of non verbal Message :- To convey information through the use of diagrams.

Q3 Define drug utilization, evolution, DUE & its cycle.

→ ~~Acco~~ Definition: According to WHO, Drug Utilization evaluation is defined as the marketing, distribution, prescription and use of drug in society, with special emphasis on resulting medical, social & ~~economic~~ ^{economic} consequences.

- DUE is an ongoing authorized & systematic quality improvement process.

* Types *

There are 4 type of DUE.

(i) Drug focused: Drug utilization evaluation of a single drug or class of drug is tested.

(ii) Indication focused: Evaluation of drug or drug that is used for specific indication is examined for their use.

(iii) Quantitative: Include collection, organizing ~~the & others~~

(iii) Quantitative: Include collecting, organizing & estimating of drug usage in figure in the patient of drug acquisition, prescribing, dispensing etc.

civ) Qualitative :- This type of DUE helps in evaluation the quality of drug therapy & its outcome by ~~comparing~~ comparing practice with predetermined criteria & standards.

* Function *


- The committee should draft and approve the policies & procedure.
- Establish and maintain adequate means of communication in hospital administration & other relevant hospital committee.
- Medical & hospital staff should understand that the DUE programme is a continuously quality ~~improvement~~ improving designed.
- Review the data generated from study.
- Inter quarterly meeting may be sufficient.
- The committee should develop a review standard and criteria of DUE studies based on knowledge, experience & literature finding.

* Rule *

- ① Planning, organizing & implementation a DUE
- ② Programme, development, supervision & conduct
- ③ Education of hospital staff about DUE in conceptual or practical exam.

- 4. Promotion of goal and objective of DUE
- Development of data collection, analysis & report writing.
- Publication of result in peer-viewed journal.

* DUE cycle.



Step 1:- Planning

- Identify drug or therapeutic ~~to~~ area of practice for possible inclusion in the programme.
- ABC or VEN analysis is another tool used to identify high priority or target drug.
- It divide as

Class A drug : 75-80% of total value of drug consumed or purchased and higher cost or highest volume item.

Class B :- It consist 15-20% of expenditure
class C :- It consist 5-10% of expenditure.

- Step 2 :- Design of Study

- Research method.

- It also divide into

- (a) Observational research method
- (b) Experimental method
- (c) Cross-sectional studies

- Other Design methods are

- prospective ; ~~concurrent~~
- concurrent
- retrospective etc.

- Step -3 Define criteria & Std.

- After the DUE target has been selected, it is important to conduct a comprehensive literature review.

- Step 4. Design the data collection.

- It is imp to limit data collection to only most imp drug.

- It is imp to limit data collection to only the most important and relevant aspect of drug and to factor which may influence these

Step 5 :- Data collection

- Data collection should be chosen carefully and should be familiar with how information is arranged in patient care notes.

- Step 6 :- Evaluation result

- Data evaluation is one of most critical step in DUE.
- To summarize the main categories of result & to identify where exactly the data show deviation are evaluated.

Step 7 :- Provide feedback of result.

Step 8 :- Develop & implement intervention

Step 9 :- Re-evaluate to determine if drug use has improved.

Step 10 :- Re-access & revise the DUE programme

Q4

Discuss its objective and guideline for patient medication history interview.

→

Q5

Draw medication chart review.

- Fundamental responsibility of clinical pharmacist.
- It is a systematic review of a patient's drug therapy to ensure that the prescribed medication is appropriate for patient.
- Involve assessment of all current & recent medication orders including route, medication and over the counter drug.
- * Goal of medication chart review
 - Ensuring that Patient receive
 - Right drug
 - Right dose
 - Right frequency
 - Right duration
 - Right dosage form

* Steps *

1) Collection & interpretation of patient specific information, including medication history interview.

- Need to collect information that will assist them to determine the appropriateness of drug therapy
- Understand the patient diseases, condition, indication of drug & daily clinical progress.

2) Assessment of Therapeutic goal.

- To determine the appropriateness of drug therapy it is essential to understand the therapeutic goal for the individual patient.
- May include one or more of following
 - Cure of diseases
 - Reduction or elimination of sign and symptoms
- Therapeutic goal should be based on patient individual circumstance & may differ from patient to patient based on their age, co-morbidities & nature & severity of their illness

3) Identification of drug related problem.

- Reviewing drug therapy should be aimed at identifying and resolving any drug related problem.
- A drug related problem is any event or circumstance involving drug-therapy that interferes or potentially interferes with the patient achieving an optimum outcome of medical care.

4) Individualising medication regimen.

- Once DRP relating to the individual drug on medication chart have resolved, the next step is to consider the patient overall medication regimen.
- Important for patient with chronic diseases or those who are on many drugs on long term basis.

5) Monitoring treatment outcomes.

- Key to assess whether the therapeutic goal of drug treatment achieved or not.

- Date _____
Page _____
- Includes review of patient clinical status, laboratory data and other markers of drug therapy response.

6. Medication chart Endorsement.

- chart endorsement is one of primary responsibilities of the pharmacist in ensuring that medication orders are unambiguous, legible and complete.

7. Documentation

- Pharmaceutical care provided should be an integral part of patient medical records.
- Documentation of pharmaceutical care provided can be made either in medication chart or in case note with a clear title with pharmacist's signature.

Q6] Write a note on pharmacist intervention in drug therapy monitoring. Classify adverse drug reaction & example in detail.

→ The clinical pharmacist should provide advice to medical staff on appropriate use and timing of TDM & assist in interpretation of result.

It involved in

- Initial selection of drug regimen.
This may involve decisions about the drug choice, dose, dosing interval, route of administration, dosage form etc.
- Adjustment of dosage regimen based on TDM result & patient clinical response.
- Dose adjustment for patient on haemodialysis or peritoneal dialysis. Provision of poisoning information.
- Adverse drug reaction.
 - According to WHO define an adverse drug reaction as 'any response to a drug which is noxious & unintended. ~~and~~ ~~which occur at dose normally used~~'.
 - There are 6 type of adverse drug reaction

Definition:

An ADR is a response to a medicine which is noxious and unintended and which occurs at doses normally used.

Type of reaction	Features	Examples	Management
Dose related (augmented)	Common Related to a pharmacological action of the drug Predictable Low mortality	Toxic effects: Digoxin toxicity; serotonin syndrome with SSRI's Side effects: Anticholinergic effects of tricyclics, Antidepressants	Reduce dose or withhold. Consider effects of concomitant therapy
Non dose related (Bizarre)	Uncommon Not related to pharmacological action of the drug Unpredictable High mortality	Hypothalamic pituitary adrenal axis suppression by corticosteroids	Withhold and avoid in future
Dose related and time related (chronic)	Uncommon Related to the cumulative dose	Hypothalamic pituitary adrenal axis suppression by corticosteroids	Reduce dose or withhold; withdrawal may have to be prolonged
Time-related (delayed)	Uncommon Usually dose related Occurs or becomes apparent some time after the use of the drug	Teratogenesis Carcinogenesis Tardive dyskinesia	Often intractable
Withdrawal (end of use)	Uncommon Occurs soon after withdrawal of the drug	Opiate withdrawal syndrome Myocardial ischemia	Reintroduce and withdraw slowly
Unexpected failure of therapy (failure)	Common Dose related Often caused by drug interactions	Inadequate dosage of an oral contraceptive, particularly when used with specific enzyme inducers	Increase dosage Consider effects of concomitant therapy.

Management

Q7 Write in brief for protocol for case presentation

→ Case presentation includes.

- present database

- General Data

- Medication Data.

→ There are main 4 part for case presentation

(i) Clinical Diagnosis

(ii) Paraclinical Diagnostic Procedure

(iii) Treatment

(iv) Prevention & health promotion

(I) Clinical diagnosis

(a) Identify data from database which can serve as :

- Age / Sex
- Symptoms
- Sign.

(b) Based on pattern recognition & prevalence, decide on the primary secondary diagnoses.

- Primary diagnosis is what you think is most likely diagnosis and Secondary diagnosis is closest second.

(c) Illustrate / explain how you arrive to 1° & 2° clinical diagnosis.

- Use the clinical diagnostic process of pattern recognition & prevalence

- use algorithm as much as possible.

(II) Paraclinical Diagnostic Procedure:

(a) Restate your primary and secondary clinical diagnosis

(b) Decide on whether you need a paraclinical diagnosis.

(c) Select two main procedure which give closest result to any diseases.

(d) Present the paraclinical diagnostic procedure that were done on patient

starting with one that you are recommending.

(III) Treatment.

(a) State your pretreatment diagnosis
1° & 2°.

(b) State goal of treatment for 1° diagnosis.

(c) Decide on treatment modality.

(d) Decide how you evaluate the result or outcome of your proposed treatment.

(e) If data are available, present the treatment procedure done on patient and their outcome.

(IV) Prevention & Health promotion

(a) State your final diagnosis

(b) Briefly describe how you will advise patient on prevention of disease and health promotion.

Q8 Discuss Q.A. with service of clinical pharmacist.

→ Quality assurance in clinical pharmacy is a technique used to ensure quality of practice and its outcome.

Objective and function:-

- To ensure provision of an appropriate service to patient.
- To ensure medicine need
- Monitor and evaluate standard of service provided
- To identify and minimize the risk

Quality assurance services :-

- ❑ Patient counselling
- ❑ ADR reporting
- ❑ Ward round participation
- ❑ Drug information services
- ❑ Patient interview
- ❑ Case note review
- ❑ Medication chart review
- ❑ Therapeutic consultation
- ❑ Drug interactions
- ❑ pharmacoeconomics
- ❑ Poison management
- ❑ News letters
- ❑ Initiation and conducting pharmaceutical research and development
- ❑ Hospital formulary
- ❑ Dosage adjustment calculations
- ❑ Therapeutic drug monitoring
- ❑ Therapeutic guideline preparations.

Quality assurance in QA services :-

Quality assurance in drug information services should implement standard procedures.

Evaluate every aspect of practice and to improve existing services.


Assessment techniques :-

- 1) Work load statistics
- 2) Auditing
- 3) enquirer's assessment
- 4) Peer review



Evaluation of patient counselling :-

- Self introduction and patient's introduction
- Purpose of counselling
- Use of patient profile information
- Assess about reason for therapy
- Use of verbal language
- Non-verbal behaviour
- Discuss about present facts
- Provide complete information
- Information about therapy.
- Summarize using key points



- Assessment of QA service.

- Audit :- Clinical audit is a quality improvement process that seeks to improve patient care outcome.

Type of audit

ca) Self audit

- (b) Group audit
- (c) External audit

Q9 Elaborate component of medication chart review

Ans Same as Q5

Q10 What is Ward round participation.

→ Ward round is a visit made by a medical practitioner, alone or with a team of health care professionals and medical student to hospital in-patient at their bedside to review and follow up the progress in their health.

- Atleast one ward round is considered everyday to review the progress of each patient outcome.

- Participation of pharmacist in ward round help to provide rational drug use.

Goals & Objective

- Gain an improved understanding of patient's clinical status and progress, current planned investigation & therapeutic goal.

- Optimize therapeutic management by influencing drug therapy selection, drug administration, monitoring and follow-up.
- Detect, manage and prevent, adverse reaction drug interaction
- Participate in the in-patient discharge planning
- Classification of ward rounds:
 - It divided into 4 type
 - (i) Pre-round
 - (ii) Registrar
 - (iii) Professor
 - (iv) Teaching round.

(I) Pre round :-

- Usually by intern or medical post graduate student in teaching hospital.
- Only few management decision are made during these round
- ~~From~~ Trainee clinical pharmacist may join the interview or PK in their pre round and complete the patient medication and clinical review at ~~this~~ this time.

(II) Registrar

- In teaching hospital, the registrar and the resident individually or as a team conduct ward round.
- At least once a day at a fixed time usually in morning.
- Useful round for clinical pharmacist of all level of experience to join.

(III) Professor

- In teaching hospital, the chief unit or the professor in a specialty conduct round together with other healthcare professionals.
- conducted for all patient under their care on a daily basis.

(IV) Teaching round

- In teaching hospital, academic medical staff conduct bedside clinical teaching round for resident, medical pre student, Intern, medical 2nd student & Pharm-D student.
- It is usually extensive round and is conducted

only a few time a week.

- It provides an opportunity for clinical pharmacist to improve their clinical knowledge.
- A pharmacy intervention is defined as, any action by pharmacist that directly result in a change in patient management of therapy.
- Major drug related queries that may ~~arise~~ arise during ward round are:
 - 1) Dose and frequency
 - 2) choice of medication
 - 3) Adr
 - 4) Drug interaction.
 - 5) Formulation.
 - 6) Actions
 - 7) Drug availability.
- Ward round follow-up
 - (a) completing documentation.
 - (b) Making necessary attention.
 - (c) Discussion with the patient.

Q11 Describe types, procedure & significance of
ward round participation.

Same as Q10.

Q.2 Detail pharmaceutical care concept.
w Pharmaceutical care defined as "the direct, responsible provision of medication-related care for the purpose of achieving definite outcome for that improve a patient quality of life."

- m) The outcomes are
- ① Cure of diseases
 - ② Elimination or reducing patient symptoms
 - ③ Arresting or slowing of diseases
 - ④ Preventing a disease or symptom.

* Basic Elements of Pharmaceutical Care

- ① Patient oriented
- ② Acute & chronic problem addressed
- ③ Documented system on patient record
- ④ Continuous care in systemic way
- ⑤ Emphasis on optimizing patient health quality of life
- ⑥ Emphasis on patient health education and health promotion.

u) There are 3 major function of Pharmaceutical care.

1. Identifying potential and actual drug related problems

2. Resolving actual drug related problem

3. Preventing potential drug related problems.

u) Certain function of pharmacist to perform.

- ① Collection of Data
- ② Identification of problem
- ③ Establish outcome goal
- ④ Evaluate the treatment alternative
- ⑤ Individual drug regimen
- ⑥ Monitor outcome

perbach lakhyu

Q1) There are 4 Types of Pharmaceutical care.

(1) SOAP.

(2) CORE

(3) FARM

(4) PRIME

(1) S = Subjective finding.
e.g. complains, Sign & Symptoms

O = Objective finding
e.g. laboratory data
- Physical sign

A = Assessment.

- Diagnosis or
- Possible explanation of problem

P = Planning

- Treatment

(2) C = Condition or patient need
- Include Non medical condition

O = Outcome

- Desire goal or condition needed

R = Regimen.

- Either therapeutic regimen or Behavioural regimen.

~~E = Evaluation parameter.~~

E = Evaluation parameters to assess outcome achievement.

- Efficacy
- Toxicity

(3) FARM

F = Findings

- Patient information lead to the problem

A = Assessment.

- Additional info, severity or any sort term & long term goal

R = Resolution.

- Intervention or proposed action of pharmacist.
- e.g. Counseling, Observation etc.

M = Monitoring & follow up.

- Monitoring of parameters like pain, mood, serum level etc.

(4) PRIME

P = Pharmaceutical care

R = Risk

I = Interactions

M = Mismatch

E = Efficacy.

→ Certain function of pharmacist are as

Establish pharmacist-patient relationship

↓
Collection data

↓
Interpret data

↓
Drug related problems

↓
Determine priority of drug related problems

↓
Determine desired outcome

↓
Desire Therapeutic goal

↓
Monitoring plan

↓
Implement & follow up pharmaceutical plan

Q3 Write a B.N on approaches of pharmaceutical care.

→ Systemic approaches to pharmaceutical care by pharmacist as Pencling

Q4 Element Outcome & process in detail.

Date _____
Page _____

Process

Patient requiring pharmaceutical
care services

↓
Assess the need and evaluate
the drug therapy

↓
Develop a care plan

↓
Implement the care
plan

↓
Monitor & review the
care plan

~) ① Assess the patient drug therapy.

~) Pharmacist will be able to identify
diseases related and drug therapy
related problems in consultation
with the patient & health care
provider.

~) Pharmacist review the patient opportunity
for risk factor like Age,
Gender,
Weight,
Medical history,
Current complaint,
Impairment in any organ,
Allergy to drug etc.

↪ This information mainly available in patient medical record.

↪ Interview the patient or patient.

↪ Interview the patient for the information of environmental or social factors such as home environment,
Drug use,
Family support,
Health benefit,
Perception of drug

(2) Develop the care plan to resolve drug related problem.

↪ Identify the potential & actual drug related problem.

↪ Develop the strategies to resolve them and establish patient specific goal in achieving therapeutic outcome.

(3) Implement the care plane

↪ After deciding care plane, pharmacist case note for ~~prescribe~~ implementation & make sure the implementation

② Monitor and review the care plan.

→ follow up stage in care plan.

→ consistent monitoring the care plan along with follow up also make sure the improvement in patient health care

+ Elements

① Patient oriented

② Acute & chronic problem addressed

③ Documented system or patient record

④ continuous care in systematic way

⑤ Emphasis on optimizing patient health quality of life

⑥ Emphasis on patient health education and health promotion.

⑤ Write detail ^{cause:} medication errors

(i) Insufficient or inadequate information about the patient

(ii) Lack of knowledge about drug therapy

(iii) Poor communication of drug information

- (iv) Poor hand writing
- (v) Confusion or misreading drug labelling, packing and nomenclature
- (vi) Poor drug storage & stacking
- (vii) Problems with standardization & distribution
- (viii) Poor safety assessment of drug delivery devices before purchase and during their use
- (xi) Misinterpreted verbal order
- (x) Lack of time.
- (xi) Calculation error
- (xii) Missing information

Q6 Define medication error & type of error with example & role of pharmacist in critical care management.

→ Any error in the process of ordering, transcribing, dispensing, administering & monitoring a medication is called medication error.

→ There are 11 types of error.

- ① Prescribing Error :- When there is ~~an~~ incorrect information of
 - Dose
 - Dosage form
 - Length of therapy
 - Frequency
 - Route
 - Drug concentration.

- (1) Omission Error :- Failure to administer an order dose.
- (2) Wrong time Error :- Medication administered outside the time window
- (3) Unauthorized drug Error :- Administration of medicine to patient without authorization by prescriber.
 - Medication for patient given to another patient
- (4) Improper Dose form :- Dose greater or less than prescribed one may give unwanted reaction & increase severity of diseases
- (5) Wrong Dosage form :- Different dosage form may be get administered to patient
- (6) Wrong drug preparation Error :- Oral suspension with incorrect volume.
- (7) Wrong admin technique Error :- SC that is given too deep.
- (8) Deteriorated Drug Error :- Monitoring expiration date is very important.
 - Degraded drug due to

(10) ^{Error} monitoring factor :- Inadequate drug therapy
e.g. Insufficient stock of serum
drug ~~that~~ required.

(11) Compliance Error :- Failure to adhere to
prescribed the drug regimen
e.g. - Does not complete antibiotic
therapy.

r Role of pharmacist in ICU

(1) In ward round participation to provide
pharmacotherapeutic management.

(2) Taking history & review the medication continued
to patient.

(3) Monitor patient health

(4) Monitor any adverse drug reactions

(5) Provide information of drug to ICU team

(6) Provide therapy related knowledge

(7) Ensure the safety & effective use of drug

(8) Maintain documentation for record

(9) Modification in regimen.

(10) Development & implementation of drug protocol to maximize drug benefit

Q7 Describe pharmacist approach for management of medication error

(1) Interacting with nurse about medicine

(2) Receiving & examine prescription

(3) Submitting prescription with proper editing

(4) Ensure dose strength

(5) Provide training to other workers

(6) Maintain medication profile for in & out patient.

(7) Check the dose schedule, drug interaction

(8) In any doubt immediate consult A.P.

Q. 11. Define DTC

1) DTC is a service unit operated by trained healthcare professional, who are committed to providing drug information as it relate to therapy, pharmacoeconomics education & research programs.

2) DTC provide information answers the queries

3) They keep up to date with pharmacy & therapeutic literature & disseminate relevant

• Establishment of drug information centre
① A dic should provide information proactively as well as respond to queries.

② Centre is expected to have trained staff with access to both text & computers

• Location:

1) Established in an accessible hospital or university department or any designated centre

2) Medical teaching institution

3) Pharmacy association

+ The pharmacist Role in DTC

- ① Provide medication review to patient & families, health care professionals
- ② Establishing & maintaining a formulary based on scientific evidence of safety, cost, ~~and~~.
- ③ Developing and participating in medication error, reporting and analysis program
- ④ Developing method of changing patient & provider behaviour.
- ⑤ Publish newsletters to educate patients, families & health care.
- ⑥ Educating provider about medication related policies.
- ⑦ Coordinating investigational drug services
- ⑧ Providing continuing education services to the healthcare.
- ⑨ Educate student
- ⑩ Applying health economic & outcome analysis.

Q. There are 3 types of DIC

- (1) Hospital based
- (2) Industry based
- (3) Community based

* Documentation of Drug Information request

- (1) Date & time received
- (2) Requester's name, address, method of contact
- (3) Person assessing medication information needs
- (4) Method of delivery
- (5) Classification of request
- (6) Question asked
- (7) Patient - specific information obtained
- (8) Response provided
- (9) Reference used
- (10) Date and time answered
- (11) Person responding to request
- (12) Estimated time in preparation and for communication

Q9. Write in detail systematic approach in answering DI queries

Q. There are 7 step approach by which answering the DI queries.

Step 1 :- Secure demographic of requester.

↳ The initial question show the requester knowledge.

~~Determine a method for response~~
~~this~~

- Secure name, position & anticipated knowledge of requester

Step 2 :- Obtain background information

↳ Requester name

↳ Location & method

↳ Background info must be taken in limited time

↳ Requester profession

↳ The urgency of request

Step 3 :- Determine & categorize ultimate question

↳ Referring the requester question is useful

↳ Once the ultimate question has been decided and acknowledge, the question is categorized.

↳ Categorizing help in development of search strategy.

- ii) Select the resource with highest probability of containing information.

Step 4: Strategy development & conduct search.

- ii) Categorization of ultimate question lead to search of resource.
- ii) Select the resource with highest probability of information & evaluation.

Step 5: Perform Evaluation, analysis & synthesis

- ii) Perform review on information & evaluate according to skill
- ii) Skill differentiate the professional to technician.

Step 6: Formulate and provide response.

- It involve the series of step
- Step I :- present the competing viewpoint
- Step II :- State the assessment of literature on information reviewed & claim the superior viewpoint
- Step III :- Briefly refute major strength & present weakness.

Step IV :- Defend the major strength & present weakness of inferior viewpoint.

Step V - Reiterate the final assessment in support of viewpoint

Step 7: Conduct follow up, & documentation

- i) Follow up is process of verifying the appropriateness, correctness, & completeness of response
- ii) Follow through is the process of readdressing a request based on availability of new data or a change in situation or circumstances
- iii) The ultimate question
 - Material searched
 - The response and
 - follow up are documented.

Q10 Discuss organization & information of prison information centre

Organization of PIC.

- i) For organizing PIC the question should carefully considered

- ① To whom will the services be offered initially?
- ② Will it be 24 hr?
- ③ How will it be expanded?
- ④ How will advertised to user population?
- ⑤ What are the initial & subsequent staffing requirements?
- ⑥ Are the telephone & other communication system adequate.
- ⑦ How to collect full data range from information services
- ⑧ How reliability, accuracy, & usefulness of data be evaluated
- ⑨ How data are updated.
- ⑩ Who will access ~~to~~ to what type of data & who can modify
- 11) For centre to operational it is necessary to
 - ① Obtain certain essential literature
 - ② Provide the basic training to staff
 - ③ Print forms for collection of information
 - ④ Recorder for the calls & cases
 - ⑤ compilation of files on chemical used in local product.

- i) Information on commercial product.
- ii) Most existing poison information centers began by organizing card indexes of basic information of each toxic substance. ~~as natural~~.
- iii) Although this type of information can now be stored in computer files.
- iv) The database should have entries on all product, such as:
 - pharmaceuticals
 - household product
 - pesticides
- v) Every poison information centre will have to organize & maintain its own files.
- vi) Poison information are extracted from local pharmacopoeias & government registries.
- vii) Computerized files are generated for natural toxins, poisonous plant & venomous animal.
- viii) Collected data are stored in database.
- ix) Standardized recording of enquiries, including clinical case, will ~~also~~ allow the centre to:
 - Own clinical data
 - Implement toxicovigilance

- Support Statistical studies
- Continuously evaluate the quality & efficiency of its services.

Q12 ^{component} S.N on ~~evolution~~ of biomedical literature.

- It is greater challenge to review the biomedical literature
- Knowledge of standard anatomy of article assist the reader to review the Biomedical literature easily
- Literature evolution is a process of reading & evaluating article, journal, literature & scientific study in systematic way
- It help to develop skill to make true judgement of scientific literature
- Scientific study
 - It is a written & published report that describes original research result
 - Scientific study are written in a style that is exceedingly clear
- A well written scientific literature explain the author's interest.

- iv) Author should summarize & give an idea on previous research, and reader should be able to distinguish between previous & current study only.
- v) Critical appraisal :-
 - It is process of systematically examine research evidence to assess its validity, result & relevance.
- vi) It is a way to assess the scientific value & first worthiness of study published in research article.
- vii) Selecting the article
 - 1st step in evaluation of literature is to select an article which has a greater impact in clinical practice.
- viii) Initially, read the title, authors & abstract.
- ix) ~~The~~ The title should be comprehensive that the reader can efficiently analyze the article potential.
- x) Reading :- Reviewing begins with reading & understanding the abstract or short summary that give a brief background about the research.

Initial reading give concept of objective, methodology, result & proposed significance of study.

Q11 Evaluate the biomedical literature.

1. Title :- It should be
It show depth & breadth of current study & indicate methodology used.

→ Evaluation of title.

① Based on title reader cannot review or discard the study.

② Title should not contain abbreviation, proprietary name, chemical formula, & jargon.

③ Title should not reflect its content.

④ Title should not reflect author's reference.

Q12 Abstract :- An abbreviated accurate reporting the content of a document, mainly prepared by its author for publication.

→ Abstract can be defined as a summary of each section.

Evaluation:- Abstract should outline a brief summary of each section; Intro, Objective, Scope of investigation, material etc.

3. Introduction :- Two purpose in study, creating readers interest in subj & provide them with enough information

- Evaluation:- Should be clear & sound, the nature & scope of problem investigated.

4. Objective :- Here it is what author is trying to achieve

→ Specific, clear & succinct statement of intended outcome from research.

Evaluation:- (1) New health program established
(2) Implement new policies
(3) Trying to settle a controversy
(4) Showing the validity of new technique
(5) Opening up a new field.

5. Material & Method:- It purpose to decide the method used in experiment.

Evaluation:- Method used & its description should be elucidated.

- Overall length & administration of data in experiment must be mention.

(5) Study Design:- It is the 1st part of section that is utilized in doing research.
→ A sound study design support conclusion & result.

(2) Bias:- It is a systematic variation in which treatment groups under study are treated or measured differently in a consistent bias.

Types

- (1) Missing data bias
- (2) Withdrawal bias
- (3) Sample size bias
- (4) Instrument bias

(2) Statistics:- Knowledge of statistics help an individual to evaluate whether the test in a study are appropriate or not.

Evaluation:- Reader should determine whether the appropriate method or not.

② Inappropriate method will result to misleading conclusion

③ Qualitative & quantitative data are examined.

(a) Study result & analysis:- Result should be described and presented in figure, table & chart as they are heart of literature.

Evaluation - Reader should be proper understanding of study & should evaluate clinical & statistical study.

(2) Sometimes confusion present in data result due to improper data collection.

(3) In case of negative result involved in study the must be quoted.

(10) Discussion & conclusion :- It is a study provides an opportunity for the author to interpret result and explain their clinical importance by relating or comparing work or practice.

Q13 Strategy of Medication Error

- (1) Bar code medication administration
- (2) Smart infusion pump
- (3) High alert
- (4) Safe drug nomenclature
- (5) Availability of patient education
- (6) Pharmacy maintained medication administration record
- (7) Patient Education
- (8) Pharmacist role on patient care team
- (9) Discharge counselling
- (10) Integration of documentation
- (11) Patient survey

(12) Integration of documentation.

(13) Increase awareness

(14) Patient care sound

(15) Avoid brand nomenclature

(16) Beware of OTC family.

(17) Duplicate therapies should be managed

(18) Report Error to improve process

(19) Educate caregivers

(20) Educate the ~~non~~ nursing care

Q14) Enumerate LFT & LFT produce Excretory product

Ans) There are 4 type of LFT test

① Protein synthesis

- (a) Albumin
- (b) Prealbumin
- (c) PT/INR

② Excretion in bile duct & drainage into duodenum

- (a) Bilirubin
- (b) ALP
- (c) 5'-nucleotidase
- (d) GGT

③ Hepatocellular injury :-

- (a) Aminotransferase
- (b) AST
- (c) ALT

④ Detoxification : Ammonia (NH_4^+)

① Protein test

a) Albumin :- ~~plasma~~

Normal range - 4-5g/dl - Adult

1.9-4.4g/dl - children

- Critical value $< 2.5 \text{ g/dl}$

- Effect : ↑ osmotic pressure of plasma carrier protein

- Half time : 20 days

Produce : liver

Store : Serum

Secretion : liver

Effect High : Dehydration

- Anabolic steroid

- limited to underlying disorder

low :- Less hepatic synthesis

malnutrition

Protein losses

Pregnancy

Eclampsia

- SOB

Drug monitor E test - Parenteral nutrient

(b) Prealbumin

Normal range: $17-34 \text{ mg/dL}$

production - liver

~~Source~~

Release - liver

Half life: 2 days

us Use in Total parenteral nutrition monitoring.

(c) PT/INR

Normal range

PT: $12.7 - 15.4 \text{ sec}$ INR: $0.9 - 1.1$ Critical Value: PT $> 16 \text{ sec}$ INR > 5

Affected by warfarin

production: liver

Effect high: Warfarin

malabsorption

- liver disorder

- Bleeding

- Ecchymosis

B	D	I	Dim
m	m	m	
m	m	m	

low - Vitamin K antagonists

(2) Excretion in bile duct &
Drainage in duodenum

(a) Bilirubin

Normal range

D - 0.0 - 0.3 I - 0.2 - 0.8

Adult :- 0.3 - 1.3 mg/dl

pediatric :- 2 - 4 mg/dl

Critical value :- > 4 mg/dl

Prehepatic - liver

Store :- Gallbladder

Secretion :- stool & urine

Total bilirubin	Direct	Indirect	Diagnosis
Moderately high	within normal limit	moderately high	Hemolytic Gilbert Syndrome Neonatal jaundice
moderately high	moderately high	within normal limit	Congenital Syndrome, Kretz
mildly high	mildly	moderately	Hepatobiliary

(b) ALP

normal range

Adult

Varies

but reference as

44 to 147 (IU/L)

Production :- Intracellular enzyme

Storage :- liver, placenta, bone & small intestine

Effects

High :- Cholestatis

- Bone diseases

- Pregnancy

- childhood

- Underlying disorders

Low :- Vit D intoxication

Seizure

Hypothyroidism

(c) 5' nucleotidase

Normal range :- 0-11 unit/L

location :- Heart, brain, liver, blood vessel

~~High~~ within normal limit :- Pregnancy

- Markedly elevated
- Mildly elevated

cholestatic syndrome
Hepatocellular diseases

cd) Gamma-Glutamyl Transferrase (GGT)

Normal range :- 9-58 unit/L

within normal limit - Haemolysis
markedly elevated - cholestatic syndrome / Alcoholic
Moderately high :- Hepatobiliary disease

③ Hepatocellular injury

(a) AST

Normal range

10-40

Adult :- 12-38 IU/L

Infant :- 30-100 IU/L

Critical Value > 80

Description :- Intracellular enzyme
storage :- Liver, Cardiac, Kidney, brain

High :- Hepatitis

- haemolysis
- muscular disease

- MI

- Renal injury

- Pulmonary infarction

- Necrotic tumour

(b) ALT

Normal range :-

Adult :- 7 - 40 IU/L

Infant :- 6 - 40 IU/L

Critical value > 60 IU/L

production :- Intracellular ~~in~~ enzyme
store in Liver, cardiac, kidney, brain

High :- Same as AST

(c) Detoxification :- Ammonia

Normal range :-

Adult :- 19 - 60 mcg/dl

Newborn < 100 mcg/dl

~~Critical value~~

Production :- In gut

Secretion :- Liver metabolism

High :- liver failure

- Reye syndrome

- Urea cycle disturb

Hepatic Encephalopathy

Q16 ^{urine} ~~renal~~ colour & presence of cell

BUN

Creatinine

Specific gravity

- sediments

- protein

- glucose

u) u) BUN (blood urea nitrogen)

Normal range :-

Adult :- 8-23 mg/dl

Pediatric :- 5-18 mg

u) High :- ~~Renal insufficiency~~

- Renal insufficiency (obstruction or cancer)

- Urinary blockage (Stone or tumor)

- Heart failure (poor renal perfusion)

- Dehydration

- High ~~protein~~ protein diet

- Medicines ~~effect~~ elimination obstruct

- Azotemia

Low :- Malnutrition

- liver damage inhibit urea cycle, cause less urea formation & increase free ammonia
- Over hydration

(ii) Creatinine :- By product of muscle energy metabolism.

Normal range

Adult :- 0.6 - 1.2 mg/dl

Pediatric :- 0.2 - 0.7 mg/dl

High :- Dehydration

- Blood loss
- CCF
- Hypotension
- Chronic renal failure
- Glomerulonephritis
- Renal stone
- obstruction of urinary track

Low :- Older age

- Muscle mass weakness
- Malnutrition

(iii) Specific Gravity

(i) Normal range: 1.016 - 1.022

High :- Addison's disease

- Heart failure
- Loss of body fluid
- Narrowing of renal artery
- Sugar
- shock

Low :- Damage to kidney cell

- Diabetes insipidus
- Overhydration
- Low Na^+ level

(iv) Sediment

(i) Protein

Normal range: $< 200 \text{ mg}$

High :- - glomerulonephritis

Amyloid

Diabetic nephropathy

Lupus nephritis

- Multiple myeloma

- pre-eclampsia in pregnancy

Low :-

- High BP
- Lower UTE
- fever
- Renal tubular damage
- Exercise
- ccF
- Acute glomerulonephritis

(vi) Glucose

Normally very low glucose in urine
0 to 0.8 mmol/L

High :-

- low insulin level in blood
- Tubule damage
- High sugar consumption
- Diabetes

(vii) Urine Colour

① Red to Orange :- Myoglobin

- Hemolysis

- liver disorder

Drugs :- warfarin,
rifampin

Isoniazid

sulfasalazine etc

- food :- cold drink dyes

- Beets

② Blue to green :- Biliverdin
- Bacterial infection
- Drugs :- methylene blue,
Indomethacin
Amitriptyline

③ Brown to black :- Myoglobin
Bile pigment
Melanin
Methemoglobin
Drugs or chemicals

(vii) Presence of cells

① RBC :- glomerulonephritis
Tubular injury

② WBC :- pyelonephritis
- Interstitial nephritis

③ Tubular epithelial :- Necrosis
- cytomegalovirus
- Toxicity of Salicylate
& heavy metal

④ Hyaline & Granular :- Tubular necrosis
cell glomerulonephritis

⑤ Waxy cast :- Chronic renal failure

Q17 Anemia test

① RBC ~~test~~
Hgb
Hct } low in
all anemia.

② MCV } High in :- B₁₂ deficiency
MCH } folate

low in :- Iron deficiency
Anemia of chronic
diseases

③ RDW : RBC distribution width
high in :- B₁₂ deficiency
folate deficiency
Iron deficiency

④ Reticulocyte count : High in :-
- Iron
- Acute blood
loss
- Hemolytic

low in - B₁₂ deficiency
- folate
- anemia of chronic diseases

(5) Serum homocysteine
high :- B₁₂ deficiency
 folate

(6) Serum iron
low :- Iron defan
 Anemia of chronic diseases

(7) Plasma haemoglobin :- High in Hemolytic

(8) Total iron binding capacity

High :- Iron deficiency

low :- Anemia of chronic diseases

Q1 Explain in brief about various PFT.

Ans) Pulmonary function test is a grp of procedure that measure the function of lungs, revealing problem in the way of breathes.

* The Rft common test are

① Lung Volume test

~~② ERV: Expiratory reserve volume~~

① Tidal Volume (TV) :-

Range :- 500 to 700 ml

- Air inhaled or exhaled at rest

② Inspiratory volume (IC)

:- ~~Amount~~ ^{Volume} of air inhaled after TV. to maximum

:- 3.4 to 3.6 L

③ Inspiratory reserve volume

:- Amount of air inhaled after normal inhalation

:- 3.1 L

④ Expiratory reserve volume

:- Amount of air exhaled after normal exhalation :- 1.2 L

⑤ Slow vital capacity (SVC)

∴ full inhalation - exhalation procedure perform slowly ~~is~~ called SVC

⑥ Residual Volume

Amount of air left in lung after full exhalation

- 1.2 L

⑦ Functional residual capacity

∴ Amount of air remain after TV

- 2.4 L

⑧ Vital Capacity

∴ $TV - RV$

∴ 5000 ml

⑨ Total lung capacity

Total amount of air 6. L

② lung flow test.

① Forced expiratory volume

- change in FVC measurement show airway obstruction.

Normal value: FEV₁ = 0.75 - 5.5 L

② Peak expiratory flow rate

- Maximum airflow rate measure
400 - 900 L/min

③ Forced expiratory flow

FEF = 25 - 75

→ Disease & values

① Obstructive lung diseases, chronic

↓ FEV₁/FVC

↓ FEV₁

- FVC

RV

TLC

↑ Res on

② Obstructive lung disease, reversible or stable

All @

③ Restrictive lung - Test FEV/FVC
disease

FEV
FVC
RV
TLC } values

④ Mixed obstructive & restrictive - Test FEV/FVC
values
FEV
FVC
TLC

Test @ RV

+ ⑤ Specialized test.

① Bronchial Provocation Test.

∴ Used to diagnose asthma.

- Effect of drug therapy evaluation
- Evaluate drug adverse or hyperactivity

Normally negative / If +ve than asthma

② Exercise challenge Testing

- Use to diagnose exercise induce bronchospasm (EIB)

Q2 Component of patient case history

Ans The patient case history has main 5 primary component that are

- ① Medical history
- ② Laboratory & diagnostic test
- ③ Problem list
- ④ Clinical note
- ⑤ Treatment note

① Medical history

The medical practitioner interrogate patient to obtain following info.

(a) Identification & demographics: Name,
Address,
Occupation,
Age,
Sex,
Status,
Contact number.

(b) Chief complaint :- Major health related issue or problem ~~as mentioned~~ perceived by patient.

(c) History of present illness :- Include Complaint, enumerate in C.C

(d) Past medical history :- Include

Q2 LFT test cholestasis & cirrhosis

w) There are 4 type of LFT test

① Protein synthesis

(a) Albumin

(b) Prealbumin

(c) PT/INR

② Excretion in bile duct & drainage
in to duodenum

(a) Bilirubin

(b) ALP

(c) 5'-nucleotidase

(d) ~~ALT~~ GGT

③ Hepatocellular injury

(a) Aminotransferase

(b) ALT

(c) AST

(4) Deoxygenation :- Ammonia

* Liver cholestatic liver diseases

- Cholestatic liver diseases is a condition that affect the bile duct, result in buildup of bile in liver.

(a) ALP (alkaline phosphate) :-

- Elevated level indicate liver cholestatic

(b) Gamma-glutamyl transaminase (GGT) :-

- Elevated in liver cholestatic

(c) Bilirubin :-

- It buildup in liver due to bile duct obstruction result in Elevated ~~to~~ bilirubin level.

* Liver cirrhosis

- Liver cirrhosis is a condition in which the liver tissue become scarred and damage leads to liver failure.

(a) ALT (alanine aminotransferase)
∴ Elevated level show liver damage or inflammation

(b) AST (aspartate aminotransferase)
∴ Elevated level

(c) ALP ∴ Elevated level show damage or obstruction

(d) Total Bilirubin
- Elevated level cause jaundice common in cirrhosis

(e) Albumin
- low level of albumin show liver diseases or damage

(f) Prothrombin time (PT)

- low level of clotting factor lead to delay clotting and hence prolonged prothrombin time ^{due to} results in liver damage.

Q3 Non verbal Verbal communication

Mid 1 - Q 2 CP-1

Q4 Define adr, evolution & reporting of ADR.

(u) Any ~~harmful or unintended reaction to a medication~~ that

(u) Any response to a drug which is noxious, unintended and occur at doses used as normal dose to treat therapeutic diseases

(u) There are 5 type of adverse drug reactions based on drug effect.

(u) The following are the steps involved in the evaluation of ADR.

ci) suspected ADR identification

- This is the first step

- Suspected adr can be identified through various sources by health workers, patient and caregiver

cii) Causality assessment :- This is the next step of evaluation

- It involves determining which medication likely cause the ~~adr~~ adr or any other factor involved

- The assessment done by using various tools like Narsing's algorithm or Uppsala Monitoring Centre.

(iii) Severity assessment :- It involves determining the degree of harm caused by the reaction, mild \rightarrow moderate \rightarrow severe \rightarrow fatal.

(iv) Frequency assessment :- Involves determining how often the reaction occurs in patient taking medication.

(v) Risk assessment :- Last and final step is risk assessment.

- This involves, assessing the risk of ADR occurring in patient taking medication compared to benefit outweigh the risk associated with ADR.

(vi) Dose response relationship :- This include dose related ADR response.

(vii) Geo-morbidity :- Presence of other medical condition or use of other medication can increase the risk of ADR.

Reporting

- 1) Identify the ADR
- 2) Collect information
- 3) Report to appropriate authority
- 4) Provide detail
- 5) Include Patient information
- 6) Describe the reaction
- 7) Follow-up notes
- 8) Use the standardized ADR form

winter.

Date _____
Page _____

(14a) Cardiac Marker.

(1) There are several types of cardiac markers

1) Troponin

2) Creatine kinase (CK)

3) Myoglobin

4) Brain Natriuretic Peptide (BNP)

5) C-reactive protein (CRP)

6) Lactate dehydrogenase (LDH)

7) Imaging techniques like.

- ECG

- Chest radiography

- Nuclear imaging

- CT scan

- MRI

- Blood Pool Imaging

* Diseases related abnormality

1) Acute myocardial infarction (AMI)

Troponin :- ↑ Yes Normal range :-

CK & MB :- ↑ Yes Normal range :-

2) Heart failure

BNP, HR & Galactin - 3 level increase

Normal

Normal range

BNP :- less than 100 pg/ml

HR :- 60-100 bpm

Galactin 3 :- less than 17.8 ng/ml

3) Angina, CAD, Arrhythmia, AF

EKG abnormalities

4) Corcha myopathy

Troponin :- Tes N :- less than 0.03 ng/ml
 CK :- Tes N :- 26-192 U/l

5) Pericarditis

CRP :- Tes

6) Myocarditis

Troponin :- Tes

ck :- Tes

CRP :- Tes N :- less than 6

7) Dilated cardiomyopathy

Troponin :- Tes

CK :- Tes

③ HCT or PCV

42 for 52%.

low :- Anemia
Over hydration
Blood loss

High :- Dehydration

④ MCV

90 - 100

low :- A
I

High :- B F deficiencies

⑤ MCHC :- 34 ± 3

low :- Hypochromia

⑥ RDW :-

High :- B ~~A~~ A
F I

⑦ Reticulocyte :- (NO. 1 to 2.4 %)

low :- Aplastic anaemia

High :- Hemolytic
B - Sickle
Iron

⑧ ESR :- 0 to 20 mm/hr

low :- C HK, Hypofibrinogen

High :- chronic infections
Neurosis
- RA
- Auto immune diseases

⑨ WBC :- 4000 to 11000 cell/mm³

low :- bone marrow depression

~~Cancer~~
- Antineoplastic agents

High :- leukemic

- Neurosis
- Infections

Consider pharm d guru
or pharm d notes
for Adverse drug classification chapter